Document ID: EPA-HQ-OPP-2002-0202-0065
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2004-09-10T04:00Z

Page
1
of
2
August
4,
2004,
Lindane
NARAP
Conference
Call
Industry
&
Registrant
Stakeholders
Meeting
Minutes
Purpose:

To
get
input
from
stakeholders
as
EPA
and
FDA
are
developing
the
US
position
on
the
North
American
Regional
Action
Plan
(
NARAP)
for
Lindane
Summary:

The
lindane
registrants
feel
that
the
US
position
for
the
NARAP
should
be
the
same
position
as
that
taken
in
the
2002
Lindane
Registration
Eligibility
Decision
(
RED).

Minutes:

The
call
started
with
an
explanation
by
EPA
of
what
the
NARAP
is,
what
has
happened
so
far,
and
the
US
role
in
developing
the
NARAP.
The
call
participants
then
discussed
the
relationship
between
EPA's
RED
and
the
NARAP.
EPA
described
the
NARAP
as
broader
in
scope
than
the
Lindane
RED.
The
following
points
were
expressed
by
the
stakeholders:

­
Stakeholders
stated
that
the
use
of
lindane
has
already
been
reduced
­
there
are
now
just
six
seed
treatment
uses,
and
rates
have
been
lowered.
­
Stakeholders
believe
that
lindane
mixed
isomers
are
the
problem
in
the
environment
and
this
problem
stems
from
their
use
in
Mexico.
­
Stakeholders
stated
that
lindane
is
not
a
Persistent
Organic
Pollutant
(
POP)
chemical.
­
Stakeholders
stated
that
residues
in
Arctic
are
other
isomers,
not
lindane
(
gamma
isomer),
which
is
what
is
registered
for
use
on
seed.
­
Stakeholders
stated
that
lindane
is
still
in
demand;
registrants
are
still
spending
money
on
developing
required
studies.
Recent
cancellations
reflect
declining
use
of
other
active
ingredients
in
end
use
products,
not
lindane
itself.
­
There
is
concern
that
politics
will
enter
into
the
NARAP
process
and
that
the
US
position
will
be
based
on
politics,
not
on
the
science.
­
Stakeholders
feel
that
the
pharmaceutical
use
of
lindane
is
not
relevant
to
the
US
position
because
they
believe
that
its
use
is
diminishing/
going
away
and
it
is
no
longer
cost
effective
to
make
pharmaceutical
grade
lindane.
­
Stakeholders
feel
that
pharmaceutical
uses
should
not
be
a
part
of
an
aggregate
risk
assessment
for
lindane.
Stakeholders
also
believe
that
if
it
was
to
be
part
of
an
aggregate
risk
assessment
for
lindane
specifically,
probabilistic
modeling
would
show
the
risk
is
not
significant.
­
Registration
of
lindane
is
expected
to
continue
in
Mexico;
registrants
do
not
expect
other
(
Mexican)
lindane
registrants
will
take
up
Bayer's
joint
cancellation
offer.
­
Crompton
Corp.
is
challenging
the
Canadian
government's
decision
on
the
cancellation
of
lindane
use
and
expects
that
the
Canadian
decision
to
cancel
their
lindane
labels
will
be
overturned
through
the
legal
process.
­
The
grower
participant
and
USDA
did
not
have
further
information
to
provide
on
use
of
lindane.
Page
2
of
2
Attendees:

US
EPA:

Kimberly
Nesci
OPP/
SRRD
Mark
Howard
OPP/
SRRD
Janice
Jensen
OPP/
FEAD
Keith
Chanon
OPP/
FEAD
Kevin
Minoli
OGC
US
FDA:
Abby
Jacobs
FDA/
CDER
Registrants:
Will
Cummings
Crompton
Sue­
Chi
Chen
Gustafson
Dennis
McFadden
Gustafson
Jeff
Hartman
Gustafson
Orval
Swenson
Agsco
Michel
Paupy
Inquinosa
Vincen
Galvin
Inquinosa
Industry
Consultants
Ed
Johnson
Technology
Sciences
Group
Inc
Gary
Burin
Technology
Sciences
Group
Inc
Chuck
O'Conner
McKenna
Long
&
Aldridge
LLP
Michael
Bocher
McKenna
Long
&
Aldridge
LLP
USDA:
Dhol
Herzi
National
Corn
Growers
Association:
Betsy
Croker